Autologous adoptive T-cell therapy in which patient-derived tumor-reactive T cells are expanded ex vivo and reinfused to recognize peptide-HLA complexes via native T-cell receptors, activating cytotoxic effector functions (perforin/granzyme and cytokines) to kill tumor cells.
Autologous tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor peptide–HLA complexes via their native T‑cell receptors, triggering TCR signaling and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to kill tumor cells.
YES
DIRECT
Tumor-reactive T cells recognize the tumor peptide–HLA-DR complex via their native TCR, triggering cytotoxic granule release (perforin/granzyme) and Fas–FasL signaling to induce apoptosis of target cells.
Autologous adoptive T-cell therapy in which patient-derived tumor-reactive T cells are expanded ex vivo and reinfused to recognize peptide-HLA complexes via native T-cell receptors, activating cytotoxic effector functions (perforin/granzyme and cytokines) to kill tumor cells.
Autologous tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor peptide–HLA complexes via their native T‑cell receptors, triggering TCR signaling and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to kill tumor cells.
YES
DIRECT
Infused tumor-reactive T cells recognize the tumor peptide–HLA-DQ complex via their native TCRs and directly kill target cells through perforin/granzyme release and Fas–FasL–mediated apoptosis.
Autologous adoptive T-cell therapy in which patient-derived tumor-reactive T cells are expanded ex vivo and reinfused to recognize peptide-HLA complexes via native T-cell receptors, activating cytotoxic effector functions (perforin/granzyme and cytokines) to kill tumor cells.
Autologous tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor peptide–HLA complexes via their native T‑cell receptors, triggering TCR signaling and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to kill tumor cells.
YES
DIRECT
Infused tumor-reactive T cells recognize the tumor peptide–HLA-DP class II complex via their native TCR and directly kill target cells by cytolytic synapse formation with perforin/granzyme release (and Fas–FasL apoptosis).
IgG-based CD3×FcRH5 bispecific T-cell engager (RO7187797) that binds FcRH5 on myeloma plasma cells and CD3 on T cells to redirect cytotoxic T-cell killing.
IgG-based bispecific antibody that binds FcRH5 on myeloma plasma cells and CD3 on T cells, bringing them into proximity to activate T cells and redirect cytotoxic killing of FcRH5-expressing tumor cells.
YES
DIRECT
Bispecific antibody binds FcRH5 on tumor cells and CD3 on T cells, forming an immune synapse that activates T cells to release perforin/granzymes and kill FcRH5-expressing cells.
IgG-based CD3×FcRH5 bispecific T-cell engager (RO7187797) that binds FcRH5 on myeloma plasma cells and CD3 on T cells to redirect cytotoxic T-cell killing.
IgG-based bispecific antibody that binds FcRH5 on myeloma plasma cells and CD3 on T cells, bringing them into proximity to activate T cells and redirect cytotoxic killing of FcRH5-expressing tumor cells.
NO
INDIRECT
Cevostamab links CD3 on T cells to FcRH5 on myeloma cells, activating T-cell cytotoxicity (perforin/granzyme-mediated killing) against FcRH5+ tumor cells; CD3E-expressing T cells are not targeted for killing.